ERBB2 and breast carcinoma: While molecular subtypes have been previously evaluated in HER2-positive breast cancer, we are the first to compare the effects of neoadjuvant chemotherapy combined with trastuzumab and pertuzumab versus trastuzumab only within different molecular subtypes, in relation to both pCR as well as survival outcomes, in such a large sample size.